202 related articles for article (PubMed ID: 35784354)
1. CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment.
Pei Y; Xiang Z; Wen K; Tu CR; Wang X; Zhang Y; Mu X; Liu Y; Tu W
Front Immunol; 2022; 13():872122. PubMed ID: 35784354
[TBL] [Abstract][Full Text] [Related]
2. CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against influenza virus.
Pei Y; Wen K; Xiang Z; Huang C; Wang X; Mu X; Wen L; Liu Y; Tu W
Signal Transduct Target Ther; 2020 Jun; 5(1):74. PubMed ID: 32488072
[TBL] [Abstract][Full Text] [Related]
3. Targeted activation of human Vγ9Vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease.
Xiang Z; Liu Y; Zheng J; Liu M; Lv A; Gao Y; Hu H; Lam KT; Chan GC; Yang Y; Chen H; Tsao GS; Bonneville M; Lau YL; Tu W
Cancer Cell; 2014 Oct; 26(4):565-76. PubMed ID: 25220446
[TBL] [Abstract][Full Text] [Related]
4. Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment.
Wang X; Zhang Y; Mu X; Tu CR; Chung Y; Tsao SW; Chan GC; Leung WH; Lau YL; Liu Y; Tu W
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35105688
[TBL] [Abstract][Full Text] [Related]
5. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
6. γδ T Cells in Tumor Microenvironment.
Imbert C; Olive D
Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
[TBL] [Abstract][Full Text] [Related]
7. Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.
Tomogane M; Sano Y; Shimizu D; Shimizu T; Miyashita M; Toda Y; Hosogi S; Tanaka Y; Kimura S; Ashihara E
Biochem Biophys Res Commun; 2021 Oct; 573():132-139. PubMed ID: 34407491
[TBL] [Abstract][Full Text] [Related]
8. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
Dhar S; Chiplunkar SV
Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
11. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
12. Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vγ9Vδ2 T cells in low levels of IL-2.
Cho HW; Kim SY; Sohn DH; Lee MJ; Park MY; Sohn HJ; Cho HI; Kim TG
J Leukoc Biol; 2016 Apr; 99(4):521-9. PubMed ID: 26561569
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
14. Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
Giannotta C; Autino F; Massaia M
Front Immunol; 2023; 14():1167443. PubMed ID: 37143664
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-18 activates Vγ9Vδ2
Murday AS; Chaudhry S; Pauza CD
Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
[TBL] [Abstract][Full Text] [Related]
16. IL-21-mediated expansion of Vγ9Vδ2 T cells is limited by the Tim-3 pathway.
Wu K; Zhao H; Xiu Y; Li Z; Zhao J; Xie S; Zeng H; Zhang H; Yu L; Xu B
Int Immunopharmacol; 2019 Apr; 69():136-142. PubMed ID: 30708194
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.
Domae E; Hirai Y; Ikeo T; Goda S; Shimizu Y
Oncotarget; 2017 Jul; 8(28):45928-45942. PubMed ID: 28521284
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Etxeberria I; Bolaños E; Teijeira A; Garasa S; Yanguas A; Azpilikueta A; Kavanaugh WM; Vasiljeva O; Belvin M; Howng B; Irving B; Tipton K; West J; Mei L; Korman AJ; Sega E; Olivera I; Cirella A; Ochoa MC; Rodriguez ME; Melero A; Sanmamed MF; Engelhardt JJ; Melero I
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34172583
[TBL] [Abstract][Full Text] [Related]
19. CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes.
DeBarros A; Chaves-Ferreira M; d'Orey F; Ribot JC; Silva-Santos B
Eur J Immunol; 2011 Jan; 41(1):195-201. PubMed ID: 21182090
[TBL] [Abstract][Full Text] [Related]
20. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
Zhai X; You F; Xiang S; Jiang L; Chen D; Li Y; Fan S; Han Z; Zhang T; An G; Zhang B; Chen Y; Meng H; Yang L
Am J Cancer Res; 2021; 11(1):79-91. PubMed ID: 33520361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
